China syndrome - a regulatory framework in meltdown?
Article Abstract:
The hopes of the Chinese State Food and Drug Administration (SFDA) are dashed with tragic personal consequences for Zheng Xiaoyu and allegations of widespread corruption by Chinese officials. Zheng's execution and life imprisonment of his subordinates have highlighted the intention of the Chinese authorities to make a strong public statement that corruption will not be tolerated by the SFDA.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Lack of private financing hobbles emerging biotech regions
Article Abstract:
The initiatives taken by the Governments of the largest emerging economies including China, India and Russia to develop their biotech sectors are hindered by the lack of an appropriate level of private funding. They also badly need more intellectual property protection and help for enterprise creation as well as the definition of niche areas to focus on.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Publicity and the regulator: Striking a balance. Mind the cap. E&Y faces Equitable grilling
- Abstracts: Boeing reports mixed bag of military aircraft sales. Boeing probes seen continuing, but not harming revenues
- Abstracts: Gold in the ivory tower: Equity rewards of outlicensing. Who took the tech out of biotech? The hermit crab solution
- Abstracts: The policy outlook from the Hill. Action needed to harmonize regulation of low-level presence of biotech traits
- Abstracts: Investment and financing constraints: evidence from the funding of corporate pension plans. The foundations of freezeout laws in takeovers